Health Economics›Colon cancer›Adjuvant therapy

Adjuvant therapy

Colon cancer · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
mFOLFOX6 and Cetuximab Variant #02	RAS	R 76 618	14d	~8.2 mo	~30.9 mo	~18	~R 1 379 118 PFS proxy · indirect	4
mFOLFOX6-B Variant #01	—	R 12 127	14d	~9.7 mo	~29.0 mo	~22	~R 266 798 PFS proxy · indirect	12
FLOX Variant #01	—	R 10 333	56d	—	—	—	—	—
Tegafur, Uracil, Folinic acid Variant #01 Partial	—	R 2 956	35d	—	—	—	—	—
mFOLFOX6 Variant #02	—	R 2 466	14d	~8.4 mo	~12.7 mo	~19	~R 46 863 PFS proxy · indirect	15
mFOLFOX6 Variant #02	RAS	R 2 466	14d	~8.4 mo	~12.7 mo	~19	~R 46 863 PFS proxy · indirect	15
CapeOx Variant #01	—	R 2 384	21d	—	—	—	—	1
Capecitabine monotherapy Variant #17	—	R 2 219	21d	—	—	—	—	1
FOLFOX4 Variant #01	—	R 2 064	14d	—	—	—	—	1
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 1 629	14d	—	~11.8 mo	—	—	3
FULV Variant #01	—	R 1 466	35d	—	—	—	—	1
SOX Variant #01 Partial	—	R 1 075	21d	~5.6 mo	—	~9	~R 9 677 PFS proxy · indirect	3
FULV and Levamisole Variant #01 Partial	—	R 987	35d	—	—	—	—	1
Fluorouracil monotherapy Variant #16	—	R 858	42d	—	~10.0 mo	—	—	3
MOF Variant #01 Partial	—	R 759	70d	—	—	—	—	—
Fluorouracil and Levamisole Variant #01 Partial	—	R 433	28d	—	—	—	—	1
Edrecolomab monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
BCG vaccine monotherapy Variant #01 Partial	—	—	30d	—	~38.6 mo	—	—	1
S-1 monotherapy Variant #01 Partial	—	—	21d	~1.7 mo	~10.5 mo	~3	—	13

19 of 19 regimens shown